Public
interest groups call for corruption investigation into prescription
drug law…New
report shows corrupt deals that created Medicare Part D disaster
would not be eliminated under new rules before Congress
WASHINGTON, D.C. – With recent attention focused on
lobbying reform in Congress, two public interest groups today called
for an investigation into how former Rep. Billy Tauzin, R-La., now
head of the drug manufacturing companies' lobby in Washington,
inserted language into the drug benefit bill to help big drug
companies while he was negotiating to land a $2 million per year job
as president of PhRMA.
Rep. Marion Berry, D-Ark., who served with Rep. Tauzin on
the Medicare Conference Committee, joined leaders from the two
groups – the Campaign for American's Future and Americans United –
on a conference call with reporters today to discuss a new report of
scandals surrounding the Medicare Part D prescription drug program.
The Campaign for America's Future released a report today
that chronicles how Rep. Tauzin, R-La., former chair of the
Congressional committee overseeing the passage of Part D, worked
hard to prohibit Medicare from negotiating with drug companies to
achieve lower prices for seniors.
"The Republican leaders on the committee paid more
attention to the pharmaceutical and insurance companies who
contributed millions of dollars to their campaigns than the needs of
our seniors," said Rep. Berry. "There were even times when these
leaders shut my Democratic colleagues and I out of the room during
critical moments in this debate."
Campaign for America's Future co-director Roger Hickey
joined Rep. Berry to release the report on today's call, noting that
the failure to negotiate prices cost Part D an extra $80 billion
annually.
"Part D took billions of tax dollars that could have
provided a comprehensive, guaranteed senior citizen drug benefit and
put them into the pockets of the pharmaceutical companies," said
Hickey. "The consequences of his misconduct dwarfs villains like
Cunningham and Abramoff."
American's United communications director Brad Woodhouse also joined
Rep. Berry and Hickey on today's call. Woodhouse called Part D a
"sell-out to pharmaceutical manufacturers."
"Part D prohibits Medicare from using its bulk-buying power
to negotiate lower drug prices and denies senior citizens the choice
of a prescription drug benefit direct from Medicare," said
Woodhouse. "Part D is better for industry than it is for
pharmacists, senior citizens or patients."
Today's report examines the drug companies' $87 million in federal
campaign contributions between 1998 and 2005, including $1.5 million
to George Bush. Fully 69 percent of industry contributions went to
Republicans. Tauzin himself received $218,000 in drug money between
1989 and his departure.
Former Medicare chief Thomas Scully also receives scrutiny in the
report. Scully received an "ethics waiver" from the Bush
administration permitting him to hunt for his next job while
actively negotiating Part D on behalf of the administration. He
immediately left the administration to become a health industry
lobbyist.